IL6 and COVID-19: The release of proinflammatory cytokines, i.e., TNFα, IL-6, and IFN-β, and the durable increase in activated monocytes and plasmacytoid dendritic cells, promote a state of persistent inflammation in patients with long-term COVID-19 symptoms [31,32].